Abeona Therapeutics Doses First Patient in Phase 1/2 Trial With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA) May 17, 2016
Abeona Therapeutics Announces First Quarter 2016 Summary Financial Results and Recent Operational Highlights May 16, 2016
Abeona Therapeutics Appoints Christine Silverstein as Vice President of Investor Relations May 3, 2016
Abeona Therapeutics to Present at Gene, Cell and Molecular Therapies for Inherited Metabolic Diseases Meeting Apr 15, 2016
Abeona Therapeutics to Present at Alliance of Regenerative Medicine's (ARM) 4th Annual Cell & Gene Therapy Investor Day Mar 21, 2016
Abeona Therapeutics Announces Fourth Quarter and Full Year 2015 Summary Financial Results and Recent Operational Highlights Mar 8, 2016
Abeona Therapeutics Highlights New Preclinical Juvenile Neuronal Ceroid Lipofuscinosis (JNCL) Data at WORLDSymposium(TM) 2016 Mar 2, 2016
Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Systemic AAV Phase 1/2 Clinical Study With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA) Feb 29, 2016
